Prevention of cytomegalovirus disease in recipients of solid-organ transplants.
about
Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.Controlling cytomegalovirus: helping the immune system take the leadComparative quantitation of cytomegalovirus (CMV) DNA in solid organ transplant recipients with CMV infection by using two high-throughput automated systems.Late hepatic allograft dysfunction.Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts.Beta-herpesvirus challenges in the transplant recipient.Comparison of Real-time PCR to ELISA for the detection of human cytomegalovirus infection in renal transplant patients in the Sudan.Paradoxical rising cytomegalovirus antigenemia during preemptive ganciclovir therapy in hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes.Human embryonic stem cells: a potential source for cellular therapy.Management of opportunistic infections in solid-organ transplantation.Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins.Screening and Monitoring for Infectious Complications When Immunosuppressive Agents Are Studied in the Treatment of Autoimmune DisordersHuman cytomegalovirus-specific T-cell immune reconstitution in preemptively treated heart transplant recipients identifies subjects at critical risk for infectionStrategies for the prevention of infection after solid organ transplantation.Protective CD8+ T-cell responses to cytomegalovirus driven by rAAV/GFP/IE1 loading of dendritic cellsCytomegalovirus infection in renal transplantation: clinical aspects, management and the perspectives.Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients.Multiplex, quantitative, real-time PCR assay for cytomegalovirus and human DNA.Monitoring of viral load by quantitative plasma PCR during active cytomegalovirus infection of individual liver transplant patients.Measurement of human cytomegalovirus loads by quantitative real-time PCR for monitoring clinical intervention in transplant recipientsMonitoring of cytomegalovirus infection in solid-organ transplant recipients by an ultrasensitive plasma PCR assay.Cytomegalovirus transmission in pediatric renal transplant recipients during the window period.Comparison of quantitation of cytomegalovirus DNA by real-time PCR in whole blood with the cytomegalovirus antigenemia assay.Preemptive strategy for ganciclovir administration against cytomegalovirus in liver transplantation recipients.Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report.Viral infection in renal transplant recipients.
P2860
Q28362995-589EF835-A64C-430E-9A6D-CA604E99A316Q33345650-358F5349-085C-4B67-8DD9-E1667E909FCBQ33820695-E67C6170-7F57-4AF8-BB01-B6E6ABEFA3D7Q33974336-1B174CCC-FE8F-4EA4-BD43-1E99F8C3D6F5Q34426400-4328EF22-324A-4074-BC64-E0185D00171AQ34481742-FB89B02C-865B-4A8A-9C2A-F9C040266E37Q34918418-3AF117A4-B127-49B7-9D3B-4AB090E1C29CQ35038604-ECD6B6EA-DCCD-4802-9EFC-D89C86D3BE24Q35598906-1198CE24-2A8F-4709-B431-D6EB8482BFE0Q35661046-C6448598-57BD-4144-B9B3-6134BE89CE50Q35841369-F33B5155-4D33-4196-8AA9-0DEE28F2364FQ35946943-6388DFD4-C068-4995-A490-DCDBEB4870F7Q36009655-40DBBAFC-68B4-43B5-B2A1-8C68D2204F91Q36023008-8CE8954E-80AD-4446-8CF1-7A52D365088BQ36670902-1CCA5088-0764-497D-BA82-845A0D91F7C9Q36944377-0D9131E8-1FE5-44B7-8CE2-EB12E778B515Q37098580-47B22A94-31CE-46C8-89E4-D4BE5B3D53EDQ37724248-BE429FA8-E692-4AF6-BCF8-76E187B6A239Q39627926-C7D0C4CD-7461-4399-8AC9-2D1A01E15E90Q39628374-FE64CB4C-F146-463D-A53C-5B76E29554A0Q39732759-27B445D9-CA5C-4592-8D4F-C7F7A6443B9DQ39848377-4455B8BB-F7E7-4442-B3F0-58EF9CE4B5EBQ40862316-BDE59070-F430-4701-80E9-F6803BDE1189Q41566881-ED419856-4455-4C48-92F9-289CF380B201Q44249073-4630F492-8F41-42B9-9982-1991B027DE3FQ44899005-4BD46AD6-FF9D-4A3B-90EC-03D59636D999Q51594265-7F9DCC4A-1882-443B-AA64-BDF8FF96EB29
P2860
Prevention of cytomegalovirus disease in recipients of solid-organ transplants.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Prevention of cytomegalovirus disease in recipients of solid-organ transplants.
@ast
Prevention of cytomegalovirus disease in recipients of solid-organ transplants.
@en
Prevention of cytomegalovirus disease in recipients of solid-organ transplants.
@nl
type
label
Prevention of cytomegalovirus disease in recipients of solid-organ transplants.
@ast
Prevention of cytomegalovirus disease in recipients of solid-organ transplants.
@en
Prevention of cytomegalovirus disease in recipients of solid-organ transplants.
@nl
prefLabel
Prevention of cytomegalovirus disease in recipients of solid-organ transplants.
@ast
Prevention of cytomegalovirus disease in recipients of solid-organ transplants.
@en
Prevention of cytomegalovirus disease in recipients of solid-organ transplants.
@nl
P2860
P356
P1476
Prevention of cytomegalovirus disease in recipients of solid-organ transplants.
@en
P2093
P2860
P304
P356
10.1086/318724
P407
P577
2001-02-06T00:00:00Z